{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:20:03Z","timestamp":1781306403424,"version":"3.54.1"},"reference-count":126,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151345","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:40:50Z","timestamp":1684165250000},"page":"151345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Onconephrology and Thrombotic Microangiopathy: Looking Beyond the Horizon"],"prefix":"10.1016","volume":"42","author":[{"given":"Prakash","family":"Gudsoorkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0001","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNH.0000000000000499","article-title":"Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition","volume":"28","author":"Hanna","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2021.11.006","article-title":"Thrombotic microangiopathy syndromes-common ground and distinct frontiers","volume":"29","author":"Hanna","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0003","article-title":"Severe vitamin B12 deficiency in pregnancy mimicking HELLP syndrome","volume":"2019","author":"Govindappagari","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0004","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/toxins12020067","article-title":"Shiga toxin-associated hemolytic uremic syndrome: a narrative review","volume":"12","author":"Joseph","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151345_bib0006","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1177\/0300060519864808","article-title":"Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy","volume":"47","author":"Hanna","year":"2019","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0007","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.13581021","article-title":"How I treat complement-mediated TMA","volume":"17","author":"Sperati","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000512227","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report","volume":"11","author":"Torres","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmed.2020.00293","article-title":"Diverse clinical presentations of C3 dominant glomerulonephritis","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151345_bib0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0013","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.12112","article-title":"Complement activation in thrombotic microangiopathies","volume":"160","author":"Feng","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0014","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0016","article-title":"Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.kint.2020.05.025","article-title":"Thrombotic microangiopathy in a patient with COVID-19","volume":"98","author":"Jhaveri","year":"2020","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0018","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1681\/ASN.2020050699","article-title":"COVID-19-associated kidney injury: a case series of kidney biopsy findings","volume":"31","author":"Sharma","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0019","article-title":"Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/jcm11030790","article-title":"Complement blockade is a promising therapeutic approach in a subset of critically ill adult patients with complement-mediated hemolytic uremic syndromes","volume":"11","author":"Prevel","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0021","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-016-0537-5","article-title":"An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry","volume":"11","author":"Woodward","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0022","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/0003-4819-79-3-368","article-title":"Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases","volume":"79","author":"Lohrmann","year":"1973","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0023","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.1970.tb01433.x","article-title":"Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma","volume":"18","author":"Brain","year":"1970","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2008.06.004","article-title":"Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry","volume":"271","author":"Ishida","year":"2008","journal-title":"Cancer Lett"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151345_bib0025","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-14-1338","article-title":"Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer","volume":"20","author":"Suryawanshi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0026","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0027","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.kint.2017.04.039","article-title":"Complement-dependent, monoclonal gammapathy-associated thrombotic microangiopathy","volume":"92","author":"Schurder","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0028","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0029","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2215\/CJN.00380705","article-title":"Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?","volume":"1","author":"Brukamp","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI11088","article-title":"Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes","volume":"106","author":"Murphy","year":"2000","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0031","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/ndt\/gfq645","article-title":"The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular disease","volume":"26","author":"Hu","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25922","article-title":"Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation","author":"Heybeli","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0033","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0034","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0035","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0036","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0037","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bmt.2014.17","article-title":"Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus","volume":"49","author":"Labrador","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0038","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12185-008-0026-2","article-title":"Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients: possible involvement of graft-versus-host disease","volume":"87","author":"Kusumi","year":"2008","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0039","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ekir.2017.12.013","article-title":"Renal thrombotic microangiopathy after hematopoietic stem cell transplantation: involvement of chronic graft-versus-host disease","volume":"3","author":"Mii","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.ackd.2021.11.003","article-title":"Kidney disease following hematopoietic stem cell transplantation","volume":"29","author":"Abudayyeh","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151345_bib0042","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.semnephrol.2023.151345_bib0043","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0044","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151345_bib0045","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0046","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151345_bib0048","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151345_bib0049","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0051","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ekir.2021.03.001","article-title":"Treatment of gemcitabine-induced thrombotic microangiopathy followed by gemcitabine rechallenge with eculizumab","volume":"6","author":"Efe","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0052","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0053","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(1971)28:5<1314::AID-CNCR2820280534>3.0.CO;2-D","article-title":"Renal toxicity in man treated with mitomycin C","volume":"28","author":"Liu","year":"1971","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0054","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0055","first-page":"142","article-title":"Mitomycin\u2013C-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era","volume":"10","author":"El-Ghazal","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0056","first-page":"e23525","article-title":"Mitomycin-induced thrombotic thrombocytopenic purpura treated successfully with plasmapheresis and steroid: a case report","volume":"14","author":"Khaja","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151345_bib0057","first-page":"4501","article-title":"Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour","volume":"31","author":"Dieckmann","year":"2011","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0058","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ckj\/sft065","article-title":"Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab","volume":"6","author":"Gilbert","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0059","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1537-2995.2004.03111.x","article-title":"An immediate hemolytic reaction induced by repeated administration of oxaliplatin","volume":"44","author":"Chen","year":"2004","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0061","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO;2-N","article-title":"Carboplatin-associated thrombotic microangiopathic hemolytic anemia","volume":"64","author":"Walker","year":"1989","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0062","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Iams","year":"2013","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0063","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3892\/ol.2017.5576","article-title":"Gemcitabine-associated thrombotic microangiopathy in a patient with lung cancer: a case report","volume":"13","author":"Lai-Tiong","year":"2017","journal-title":"Oncol Lett"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151345_bib0064","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.bjc.6601001","article-title":"Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): The Netherlands Cancer Institute experience","volume":"88","author":"Schrama","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151345_bib0065","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100461","article-title":"Pegylated liposomal doxorubicin and kidney-limited thrombotic microangiopathy in a kidney transplant recipient: a case report","volume":"4","author":"Rodriguez-Ramirez","year":"2022","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0067","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00433281","article-title":"Vascular lesions following perfusion with bleomycin. Electron-microscopic observations","volume":"372","author":"Burkhardt","year":"1976","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0068","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfaa101","article-title":"Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy","volume":"14","author":"Salhi","year":"2021","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0069","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/bjh.14910","article-title":"Effective treatment of chemotherapy induced atypical haemolytic uraemic syndrome: a case series of 7 treated patients","volume":"183","author":"Weitz","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1096-8652(199908)61:4<268::AID-AJH9>3.0.CO;2-O","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report","volume":"61","author":"Leach","year":"1999","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0071","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2169\/internalmedicine.34.593","article-title":"Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case","volume":"34","author":"Sakai","year":"1995","journal-title":"Intern Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0072","first-page":"194","article-title":"Intraglomerular thrombosis with deoxycoformycin\u2013reversible acute renal failure","volume":"21","author":"Harris","year":"1984","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0073","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","article-title":"The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents","volume":"48","author":"Rowinsky","year":"1997","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0074","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151345_bib0075","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0076","article-title":"Cabazitaxel induced thrombotic microangiopathy in a patient with prostate cancer","volume":"2019","author":"Nlandu","year":"2019","journal-title":"Case Rep Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0077","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0b013e3181cea0b3","article-title":"Docetaxel-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer?","volume":"18","author":"Shrestha","year":"2011","journal-title":"Am J Ther"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0078","first-page":"634","article-title":"Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?","volume":"4","author":"Bo Kim","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0079","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1002\/ajh.25832","article-title":"Proteasome inhibitor-associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature","volume":"95","author":"Nguyen","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0081","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.17377","article-title":"Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study","volume":"193","author":"Camilleri","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151345_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0083","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0084","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0085","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0086","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0087","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0088","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0089","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151345_bib0090","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151345_bib0091","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0092","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ackd.2021.09.011","article-title":"Onco-hypertension: an emerging specialty","volume":"28","author":"Gudsoorkar","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0093","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0094","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CN110443","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case series and systematic review of the literature","volume":"96","author":"Hilburg","year":"2021","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0096","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0097","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0098","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-015-0194-5","article-title":"Palbociclib: a first-in-class CDK4\/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer","volume":"8","author":"Lu","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0099","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.clbc.2017.10.001","article-title":"Palbociclib-induced thrombotic microangiopathy in metastatic breast cancer patient surviving for 18 years: case report and review of the literature","volume":"18","author":"Raiss","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1827.2011.02704.x","article-title":"Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"61","author":"Mii","year":"2011","journal-title":"Pathol Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0102","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151345_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early elevation of complement factor Ba is a predictive biomarker for transplant-associated thrombotic microangiopathy","volume":"12","author":"Okamura","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0104","first-page":"955","article-title":"Vascular endothelial lesion in patients undergoing bone marrow transplantation","volume":"18","author":"Richard","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0105","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood-2011-02-334821","article-title":"Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system","volume":"118","author":"Luft","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151345_bib0106","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704733","article-title":"Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation","volume":"34","author":"Woywodt","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151345_bib0107","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rth2.12158","article-title":"Circulating endothelial cells as biomarker for cardiovascular diseases","volume":"3","author":"Farinacci","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jash.2011.11.003","article-title":"Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells","volume":"6","author":"Burger","year":"2012","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0109","article-title":"Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case-control study","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151345_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/br.2022.1529","article-title":"Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs","volume":"16","author":"Chebotareva","year":"2022","journal-title":"Biomed Rep"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0111","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1705976","article-title":"Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Cho","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151345_bib0112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0113","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbmt.2006.11.020","article-title":"Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151345_bib0114","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/bmt.2017.207","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies","volume":"53","author":"Khosla","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Au","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151345_bib0117","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/bmt.2008.25","article-title":"Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura","volume":"41","author":"Carella","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"1292","key":"10.1016\/j.semnephrol.2023.151345_bib0118","first-page":"72","article-title":"Successful treatment of transplant-associated microangiopathy with rituximab","volume":"122","author":"Marr","year":"2009","journal-title":"N Z Med J"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0119","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151345_bib0121","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151345_bib0122","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151345_bib0123","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","article-title":"Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study","volume":"58","author":"Svec","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151345_bib0124","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151345_bib0125","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151345_bib0126","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:42:28Z","timestamp":1759448548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000554"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151345","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onconephrology and Thrombotic Microangiopathy: Looking Beyond the Horizon","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151345"}}